ZIMLAB137.20

Zim Laboratories Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹734 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations85.896.3117.981.892.196.3108.771.888.7108.7105.394.2
Other Income1.41.11.51.01.31.81.71.52.01.76.21.0
Total Income87.297.4119.482.893.598.1110.473.290.8110.4111.495.2
Expenses
+ Cost of Materials Consumed41.051.553.531.035.539.948.627.643.543.249.743.8
+ Purchases of Stock-in-Trade2.03.02.12.73.12.53.31.62.90.62.40.5
+ Changes in Inventories-3.1-10.30.62.63.5-1.1-3.60.8-6.84.8-4.9-4.9
+ Employee Benefit Expense12.813.214.714.515.514.516.314.616.315.617.419.2
+ Finance Costs1.21.72.32.92.92.72.93.33.23.43.33.6
+ Depreciation & Amortisation4.13.93.94.95.04.95.34.95.05.05.15.4
+ Other Expenses23.827.431.323.025.129.029.622.927.031.733.633.1
Total Expenses81.890.4108.481.690.592.4102.375.791.1104.3106.5100.7
EBITDA9.311.515.68.09.511.614.64.35.812.87.22.5
EBIT5.27.611.73.14.56.79.3-0.60.87.82.1-2.9
Profit
PBT before Exceptional Items5.47.011.01.23.05.78.1-2.4-0.36.04.9-5.6
Pretax Income5.47.011.01.23.05.78.1-2.4-0.36.04.9-5.6
+ Current Tax0.81.3-1.30.30.20.73.40.10.01.51.80.0
+ Deferred Tax0.50.94.20.10.31.0-0.2-0.60.10.2-0.6-1.6
Tax Expense1.32.22.90.30.61.73.2-0.60.11.61.2-1.6
Net Income4.14.88.10.92.44.04.9-1.9-0.44.43.7-4.0
+ Net Income — Continuing Ops4.14.88.10.92.44.04.9-1.9-0.44.43.7-4.0
+ Other Comprehensive Income0.0-0.0-0.1-0.10.20.3-0.40.40.30.90.50.4
Total Comprehensive Income4.24.78.00.82.54.34.5-1.5-0.15.34.2-3.6
Net Income to Common4.14.88.10.92.44.04.9-1.9-0.44.43.7-4.0
Minority Interest0.00.0-0.00.00.00.0-0.00.00.0-0.00.0-0.0
Per Share
Basic EPS0.850.981.660.180.490.821.01-0.38-0.090.900.76-0.75
Diluted EPS0.850.981.660.180.490.821.01-0.38-0.090.900.76-0.75
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.40.40.30.90.50.4
+ Items NOT to be Reclassified to P&L-0.2-0.2-0.1-0.1-0.1-0.1-0.4-0.2-0.2-0.20.4-0.0
+ Tax on Items NOT to be Reclassified-0.1-0.1-0.1-0.10.1-0.0
+ Tax on Items NOT to be Reclassified — alt tag-0.0-0.0-0.0-0.0-0.0-0.0
+ Items to be Reclassified to P&L0.10.1-0.00.00.20.4-0.10.60.51.00.20.4
Comprehensive Income — Owners of Parent4.24.78.00.82.54.34.5-1.50.35.34.2-3.6
Comprehensive Income — Non-controlling Interests0.00.0-0.00.00.00.0-0.00.0-0.1-0.00.0-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations0.850.981.660.180.490.821.01-0.38-0.090.900.76-0.75
Diluted EPS — Continuing Operations0.850.981.660.180.490.821.01-0.38-0.090.900.76-0.75
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit45.952.161.745.650.055.160.541.749.160.158.154.7
Gross Margin %53.4954.0852.3355.7254.3057.1755.6258.1855.3155.2855.2458.09
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)5.47.011.01.23.05.78.1-2.4-0.36.04.9-5.6
Net Income Adj (tax-effected)4.14.88.10.92.44.04.9-1.9-0.44.43.7-4.0
EPS Adj0.850.981.660.180.490.821.01-0.38-0.090.900.76-0.75
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Filed Debt Equity0.000.000.000.000.000.000.000.000.000.000.000.01
Filed Dscr0.020.020.030.010.020.020.020.010.010.010.010.01
Filed Iscr0.050.050.060.010.020.030.040.000.010.030.02-0.01
Paid Up Equity Capital48.748.748.748.748.748.748.748.748.748.753.553.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.